Cyteir Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023059370 Filed on November 06, 2023

View on sec.gov

Income Statement

Concept 2023 Q3

Balance Sheet

Concept 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $129.2M
YoY Change -16.04%
Cash & Equivalents $129.2M
Short-Term Investments
Other Short-Term Assets $1.400M
YoY Change -59.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $130.6M
YoY Change -16.97%
LONG-TERM ASSETS
Property, Plant & Equipment $105.0K
YoY Change -94.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $261.0K
YoY Change -89.47%
Total Long-Term Assets $366.0K
YoY Change -91.58%
TOTAL ASSETS
Total Short-Term Assets $130.6M
Total Long-Term Assets $366.0K
Total Assets $131.0M
YoY Change -18.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $508.0K
YoY Change -69.51%
Accrued Expenses $5.500M
YoY Change 32.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.969M
YoY Change 2.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $9.000K
YoY Change -99.51%
Total Long-Term Liabilities $9.000K
YoY Change -99.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.969M
Total Long-Term Liabilities $9.000K
Total Liabilities $5.978M
YoY Change -21.99%
SHAREHOLDERS EQUITY
Retained Earnings -$162.5M
YoY Change 25.68%
Common Stock $287.6M
YoY Change 1.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $125.0M
YoY Change
Total Liabilities & Shareholders Equity $131.0M
YoY Change -18.98%

Cashflow Statement

Concept 2023 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001662244
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccountsPayableAndOtherAccruedLiabilitiesCurrent
CY2023Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40499
dei Entity Registrant Name
EntityRegistrantName
Cyteir Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5429901
dei Entity Address Address Line1
EntityAddressAddressLine1
99 Hayden Ave., Building B
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 450
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
285-4140
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CYT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129242000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
147120000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1401000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2089000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
130643000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
149209000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
105000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1699000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
261000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2324000
CY2023Q3 us-gaap Assets
Assets
131009000
CY2022Q4 us-gaap Assets
Assets
153232000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
508000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1128000
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5461000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4187000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5969000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5315000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1631000
CY2023Q3 us-gaap Liabilities
Liabilities
5978000
CY2022Q4 us-gaap Liabilities
Liabilities
6946000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36091075
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35575694
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36083742
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35516249
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
35000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
287532000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
284365000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-162536000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-138114000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
125031000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
146286000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131009000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153232000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2676000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8272000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17391000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27154000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2495000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3487000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10809000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10963000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
5171000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
11759000
us-gaap Operating Expenses
OperatingExpenses
28200000
us-gaap Operating Expenses
OperatingExpenses
38117000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5171000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11759000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28200000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38117000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1639000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
714000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4385000
us-gaap Investment Income Interest
InvestmentIncomeInterest
849000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-925000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
318000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1639000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
714000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3778000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
849000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3532000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11045000
us-gaap Net Income Loss
NetIncomeLoss
-24422000
us-gaap Net Income Loss
NetIncomeLoss
-37268000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36030474
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36030474
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35329137
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35329137
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35647202
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35647202
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35283454
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35283454
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
187292000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19000
CY2022Q1 cyt Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
39000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1255000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14102000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
174503000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2022Q2 cyt Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
32000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1365000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-12121000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
163784000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2022Q3 cyt Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
30000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
64000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1193000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-11045000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
154033000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
146286000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
42000
CY2023Q1 cyt Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
31000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
61000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1042000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12486000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
134976000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
428000
CY2023Q2 cyt Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
11000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
776000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8404000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
127787000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
133000
CY2023Q3 cyt Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
14000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
30000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
599000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3532000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
125031000
us-gaap Profit Loss
ProfitLoss
-24422000
us-gaap Profit Loss
ProfitLoss
-37268000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
368000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
498000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2417000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3813000
cyt Non Cash Lease Expense
NonCashLeaseExpense
158000
cyt Non Cash Lease Expense
NonCashLeaseExpense
551000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-925000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
318000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-686000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
179000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-620000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-119000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1940000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2912000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-6000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18872000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35615000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
312000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
303000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
303000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-312000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
92000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
603000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
31000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
695000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17874000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35832000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
147377000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
189979000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
129503000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
154147000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1908000
cyt Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
56000
cyt Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
101000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129242000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
153890000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
261000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
257000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
129503000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
154147000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">1. Nature of the business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">On June 30, 2023, Cyteir Therapeutics, Inc., (the “Company”) announced the discontinuation of development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and that the Company would initiate a plan to liquidate its assets following an orderly wind down of the Company’s operations, and return remaining cash to shareholders. On September 7, 2023, the Board of Directors of the Company unanimously approved, subject to stockholder approval, the liquidation and dissolution of the Company pursuant to a plan of liquidation and dissolution (the “Plan of Dissolution”) that includes the distribution of remaining cash to stockholders following an orderly wind down of the Company’s operations, including the proceeds, if any, from the sale of its assets. Prior to winding down operations, the Company intends to complete regulatory and patient obligations from the ongoing clinical trial. The Company has engaged independent advisors, who are experienced in the dissolution and liquidation of companies, to assist in the Company’s dissolution and liquidation. The Company has called a special meeting of its stockholders on November 16, 2023 to seek approval of the Plan of Dissolution and filed definitive proxy materials relating to the special meeting with the Securities and Exchange Commission (the “SEC”) on October 12, 2023. If the Company’s stockholders approve the Plan of Dissolution and the likelihood is remote that the Company would return from liquidation, the Company would consider liquidation as imminent and implement liquidation basis of accounting.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">CYT-0851 was being evaluated in a Phase 1 combination study with capecitabine or gemcitabine in advanced ovarian cancer and other solid tumors. The Company will continue to treat patients currently enrolled in the Company’s Phase 1/2 study of CYT-0851 as a monotherapy and in a combination study with capecitabine or gemcitabine until the conclusion of the study. Through 2022, the Company used its expertise in DNA damage response biology and a disciplined approach to select targets for other novel, differentiated programs with the aim of building a patient-centric portfolio of effective cancer therapies. In January 2023, the Company announced a strategic prioritization that included the discontinuation of these preclinical efforts.</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company was formed as a Delaware corporation on June 4, 2012, pursuant to the General Corporation Law of the State of Delaware. The Company has a principal office in Lexington, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company has incurred net operating losses since inception and has funded its operations primarily with proceeds from the sale of redeemable convertible preferred stock and the issuance of common stock in its initial public offering, or IPO. As of September 30, 2023, the Company had cash and cash equivalents of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">129.2</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> million and an accumulated deficit of $</span><span style="font-size:10pt;font-family:Arial;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">162.5</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">The Company expects that its cash and cash equivalents as of September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date these condensed consolidated financial statements are available to be issued, or until the effectiveness of the Company’s dissolution.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
129200000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-162500000
CY2022Q4 cyt Fair Value Assets Level1 To Level2 Transfer Amount
FairValueAssetsLevel1ToLevel2TransferAmount
0
CY2023Q3 cyt Fair Value Assets Level2 To Level1 Transfer Amount
FairValueAssetsLevel2ToLevel1TransferAmount
0
CY2023Q3 cyt Fair Value Assets Level1 To Level2 Transfer Amount
FairValueAssetsLevel1ToLevel2TransferAmount
0
CY2022Q4 cyt Fair Value Assets Level2 To Level1 Transfer Amount
FairValueAssetsLevel2ToLevel1TransferAmount
0
CY2023Q3 cyt Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
37000
CY2022Q4 cyt Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
786000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1023000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
982000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
324000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
304000
CY2023Q3 us-gaap Other Receivables
OtherReceivables
17000
CY2022Q4 us-gaap Other Receivables
OtherReceivables
17000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1401000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2089000
CY2023Q1 cyt Percentage Of Workforce Reduction And Preclinical Efforts
PercentageOfWorkforceReductionAndPreclinicalEfforts
0.70
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-900000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3521000
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
3018000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
503000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1822000
us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
368000
us-gaap Accumulated Depreciation Depletion And Amortization Sale Of Property Plant And Equipment1
AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
1792000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
398000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1699000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
105000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
200000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
500000
CY2023Q3 cyt Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1646000
CY2022Q4 cyt Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1356000
CY2023Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3449000
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1510000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
350000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
432000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
889000
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5461000
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4187000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holders of the common stock are entitled to one vote for each share of common stock held submitted to a vote of stockholders, and there are not any cumulative voting rights.
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10493398
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9167242
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3460897
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.60
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P8Y2M23D
CY2022Q4 cyt Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue
375000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1054357
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.69
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
457579
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1384844
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.55
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2672831
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.82
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P8Y7D
CY2023Q3 cyt Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue
1530000
CY2023Q3 cyt Share Based Compensation Arrangement By Share Based Payment Award Options Options Vested And Exercisable Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionsVestedAndExercisableGross
1439617
CY2023Q3 cyt Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAndExercisableWeightedAverageExercisePrice
6.04
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y4M13D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
575000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.78
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2000000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1800000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
889000
us-gaap Payments For Restructuring
PaymentsForRestructuring
2318000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
599000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1193000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2417000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3813000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
300000
CY2023Q3 cyt Operating Lease Liability Derecognized
OperatingLeaseLiabilityDerecognized
2200000
CY2023Q3 cyt Right Of Use Assets Derecognized
RightOfUseAssetsDerecognized
1900000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2066000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
16000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1560000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
16000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2449000
CY2023Q3 us-gaap Lease Cost
LeaseCost
18000
CY2022Q3 us-gaap Lease Cost
LeaseCost
318000
us-gaap Lease Cost
LeaseCost
393000
us-gaap Lease Cost
LeaseCost
1011000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y1M6D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
16000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
16000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2023Q1 cyt Percentage Of Workforce Reduction And Preclinical Efforts
PercentageOfWorkforceReductionAndPreclinicalEfforts
0.70
us-gaap Restructuring Charges
RestructuringCharges
4400000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-900000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
300000
us-gaap Payments For Restructuring
PaymentsForRestructuring
2300000
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
2100000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
cyt Employee Termination Related Charges
EmployeeTerminationRelatedCharges
4370000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
2052000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-059370-index-headers.html Edgar Link pending
0000950170-23-059370-index.html Edgar Link pending
0000950170-23-059370.txt Edgar Link pending
0000950170-23-059370-xbrl.zip Edgar Link pending
cyt-20230930.htm Edgar Link pending
cyt-20230930.xsd Edgar Link pending
cyt-20230930_cal.xml Edgar Link unprocessable
cyt-20230930_def.xml Edgar Link unprocessable
cyt-20230930_pre.xml Edgar Link unprocessable
cyt-20230930_lab.xml Edgar Link unprocessable
cyt-20230930_htm.xml Edgar Link completed
cyt-ex31_1.htm Edgar Link pending
cyt-ex31_2.htm Edgar Link pending
cyt-ex32_1.htm Edgar Link pending
cyt-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending